Paper Details

  1. Home
  2. Paper Details

A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.

Author: BrenAndrej, ButurovićJadranka, IvanovichPeter, KandusAljosa, KvederRadoslav, PonikvarRafael, PrimozicStanislav, VarlJanez

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the safety and effectiveness of epoetin omega and epoetin alfa in treating anemia in hemodialysis patients. Both epoetins were effective, but lower doses of epoetin omega were needed to maintain the target hemoglobin level.
Paper Details　
Original Abstract of the Article :
The objective of the study was to evaluate and compare the safety and effectiveness of epoetin omega (produced in baby hamster kidney cells) and epoetin alfa (produced in Chinese hamster ovary cells) in sustaining the correction of anemia in maintenance hemodialysis patients. The study, a prospectiv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1525-1594.2002.06844.x

データ提供：米国国立医学図書館（NLM）

Epoetin Omega vs. Epoetin Alfa for Anemia in Hemodialysis Patients

Our study delves into the vast and complex desert of kidney disease, specifically focusing on the treatment of anemia in patients undergoing hemodialysis. The goal was to compare two different types of erythropoiesis-stimulating agents (ESAs), like two camels carrying different loads in the desert, epoetin omega and epoetin alfa, in terms of their effectiveness and safety.

We conducted a controlled crossover study, which is like switching camels mid-journey to see which one is more suited for the terrain. We found that both ESAs were effective in treating anemia, but epoetin omega required lower doses to achieve the same level of hemoglobin. This is like finding a camel that can carry the same amount of water but requires less food and water to sustain its journey. No significant adverse effects were noted for either ESA.

ESAs: A Journey Through Anemia

Our findings provide important insights into the treatment of anemia in hemodialysis patients. Epoetin omega appears to be a viable alternative to epoetin alfa, offering the potential for lower dosing and potentially less cost.

Navigating the Kidney Desert

This study provides a helpful guide for navigating the complex desert of kidney disease. While more research is needed, our findings suggest that epoetin omega could be a more efficient and potentially cost-effective treatment option for anemia in hemodialysis patients. Remember, a wise traveler always chooses the best camel for their journey, just as a wise patient should choose the best treatment option for their health.

Dr.Camel's Conclusion

This research is like a refreshing oasis in the vast desert of kidney disease. It highlights the potential of epoetin omega as an effective and efficient treatment for anemia, providing valuable guidance for both patients and doctors as they navigate this challenging terrain.

Date :
  1. Date Completed 2002-04-18
  2. Date Revised 2019-09-01
Further Info :

Pubmed ID

11879235

DOI: Digital Object Identifier

10.1046/j.1525-1594.2002.06844.x

Related Literature

Article Analysis
・Side Effects of epoetin alfa injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.